SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
← catalyst calendarNCT07141329 · readout in 499 d
Sponsored by Supernus Pharmaceuticals, Inc. (industry) · SUPN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-30 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Focal Onset Seizures
Intervention
- Drug: SPN-817
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events
measured Week 1-Week 52
Permalink · SUPN's whole pipeline · Catalyst calendar · Every registered study · What changed